🚨NEW ANALYSIS: Pharma is hiking the prices of rare disease drugs after Medicare protections were weakened in the 2025 Reconciliation Package 🚨 In the first week of January, pharmaceutical companies raised prices on 208 drugs used to treat rare diseases, with over 80% of those hikes exceeding inflation. These hikes come as Congress has weakened Medicare drug price negotiation for rare disease drugs through the ORPHAN Cures Act. For patients like Ginny, who lives with LEMS and relies on Firdapse, her medication would have been eligible for negotiation before the ORPHAN Cures. Now, it is not. Congress removed one of the only tools available to lower the cost of the very drugs she relies on. The ORPHAN Cures Act does not protect patients with rare diseases. It protects pharmaceutical profits. Learn more and take action at P4AD.ORG
